NFKB2 antibody (AA 848-874)

Catalog No. ABIN3032044

Product Details anti-NFKB2 Antibody

Target: NFKB2 (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 2 (NFKB2))

Binding Specificity: AA 848-874

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This NFKB2 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Cross-Reactivity (Details): Expected species reactivity: Mouse

Purification: Antigen affinity purified

Immunogen: A portion of amino acids 848-874 from the human protein was used as the immunogen for this NFKB2 antibody.

Isotype: Ig Fraction

Application Details

Application Notes: Titration of the NFKB2 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the NFKB2 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Target Details for NFKB2

Target: NFKB2 (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 2 (NFKB2))

Alternative Name: NFKB2 (NFKB2 Products)

Synonyms: NF-kappaB2 antibody, lyt antibody, p49 antibody, p49/p100 antibody, p50B antibody, p52 antibody, nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100 antibody, Nfkb2 antibody

Background: NF-kappa-B has been detected in numerous cell types that express cytokines, chemokines, growth factors, cell adhesion molecules, and some acute phase proteins in health and in various disease states. NF-kappa-B is activated by a wide variety of stimuli, such as cytokines, oxidant-free radicals, inhaled particles, ultraviolet irradiation, and bacterial or viral products. Inappropriate activation of NF-kappa-B has been linked to inflammatory events associated with autoimmune arthritis, asthma, septic shock, lung fibrosis, glomerulonephritis, atherosclerosis, and AIDS. In contrast, complete and persistent inhibition of NF-kappa-B has been linked directly to apoptosis, inappropriate immune cell development, and delayed cell growth. NFKB1 (MIM 164011) and NFKB2 encode p105 and p100 proteins that are processed to produce the active p50 and p52 NF-kappa-B subunits, respectively. However, the p100 and p105 proteins serve regulatory functions and should not be considered exclusively as precursor forms. The most abundant activated form of NF-kappa-B is a heterodimer of the p50 or p52 subunit bound to the RELA subunit (MIM 164014). Other NF-kappa-B complexes, consisting of hetero- and homodimers of p50, p52, RELA, REL (MIM 164910), and RELB (MIM 604758), have also been detected. NF-kappa-B complexes are inhibited by I-kappa-B proteins, NFKBIA (MIM 164008) or NFKBIB (MIM 604495), which inactivate NF-kappa-B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by the kinases IKBKA (CHUK, MIM 600664) or IKBKB (MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B complex. The activated NF-kappa-B complex translocates into the nucleus and binds DNA at kappa-B-binding motifs, such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T, R is an A or G purine, and Y is a C or T pyrimidine). For reviews, see Chen et al. (1999) [PubMed 9895331] and Baldwin (1996) [PubMed 8717528].

UniProt: Q00653

Pathways: Toll-Like Receptors Cascades